[go: up one dir, main page]

AR134205A1 - Inhibidores de ripk1 y métodos de uso - Google Patents

Inhibidores de ripk1 y métodos de uso

Info

Publication number
AR134205A1
AR134205A1 ARP240102982A ARP240102982A AR134205A1 AR 134205 A1 AR134205 A1 AR 134205A1 AR P240102982 A ARP240102982 A AR P240102982A AR P240102982 A ARP240102982 A AR P240102982A AR 134205 A1 AR134205 A1 AR 134205A1
Authority
AR
Argentina
Prior art keywords
ripk1
methods
inhibitors
formula
ripk1 inhibitors
Prior art date
Application number
ARP240102982A
Other languages
English (en)
Inventor
Abdelghani Abe Achab
Yaroslav Boyko
Yi Chen
- Dimauro Erin F Heng
Duque Jenny Lorena Rico
Xavier Fradera
Anandan Palani
Barbara Pio
Meredith M Rickard
Phieng Siliphaivanh
Brandon A Vara
Jing Su
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of AR134205A1 publication Critical patent/AR134205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En el presente documento se describen compuestos de fórmula (1), o una sal farmacéuticamente aceptable de los mismos. Los compuestos de fórmula (1) actúan como inhibidores de RIPK1 y pueden ser útiles en la prevención, el tratamiento o la actuación como agente curativo para enfermedades relacionadas con RIPK1.
ARP240102982A 2023-11-02 2024-10-31 Inhibidores de ripk1 y métodos de uso AR134205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363595482P 2023-11-02 2023-11-02

Publications (1)

Publication Number Publication Date
AR134205A1 true AR134205A1 (es) 2025-12-10

Family

ID=93563555

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102982A AR134205A1 (es) 2023-11-02 2024-10-31 Inhibidores de ripk1 y métodos de uso

Country Status (4)

Country Link
US (1) US20250154173A1 (es)
AR (1) AR134205A1 (es)
TW (1) TW202523301A (es)
WO (1) WO2025096697A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4422621A4 (en) * 2021-10-27 2025-08-27 Merck Sharp & Dohme Llc SPIROTRICYCLIC RIPK1 INHIBITORS AND METHODS OF USE THEREOF
JP2024541944A (ja) * 2021-10-27 2024-11-13 メルク・シャープ・アンド・ドーム・エルエルシー スピロ三環ｒｉｐｋ１阻害薬及びその使用方法

Also Published As

Publication number Publication date
US20250154173A1 (en) 2025-05-15
WO2025096697A1 (en) 2025-05-08
TW202523301A (zh) 2025-06-16

Similar Documents

Publication Publication Date Title
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
WO2018102687A3 (en) Combination therapy for treating cancer
CL2024003232A1 (es) Compuestos derivados de heteroarilo y uso para tratar el dolor.
CO5590913A2 (es) Terapia de combinacion antivirica
CL2024003231A1 (es) Compuestos derivados de heteroarilo y uso para tratar el dolor.
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MX2020011367A (es) Compuesto oxo-sustituido.
AR128711A1 (es) Métodos para tratar carcinoma microcítico de pulmón
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
MX2025002228A (es) Metodos para el tratamiento o la profilaxis de la endometriosis
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
AR134205A1 (es) Inhibidores de ripk1 y métodos de uso
CO2025002794A2 (es) Combinaciones de compuestos antineoplásicos que comprenden un compuesto bifuncional con actividad inhibitoria de kras mutante g12d
CO2025002789A2 (es) Combinaciones de agentes antineoplásicos que comprenden un compuesto bifuncional con actividad inhibitoria de kras mutante g12d
CO2024015538A2 (es) Inhibidores de ripk1 y métodos de uso
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
MX2024010235A (es) Compuestos para su uso en el tratamiento de distrofinopatias.